

Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy 18-20 September 2025

Thursday, 18 September 2025

| 10:00 – 12:00 | Scientific Business Meetings | |
|---------------|--|---|
| | | |
| 13:00 – 13:55 | Session I: Current EBMT recommendations Chairs: Tobias Alexander (DE) & Donal McLornan (UK) | |
| 13:00 – 13:15 | EBMT recommendations for HCT in MDS | Carmelo Gurnari (IT) |
| 13:15 – 13:30 | EBMT recommendations for HCT in autoimmune diseases | Elisa Roldan Galvan (UK) |
| 13:30 – 13:45 | EBMT recommendations for CART in autoimmune diseases | Raffaella Greco (IT) |
| 13:45 – 13:55 | Panel discussion | |
| 13:55 – 15:00 | Session II: MDS diagnosis and prognosis | |
| | Chairs: Kavita Raj (UK) & Adriano Venditti (IT) | |
| 13:55 – 14:10 | MDS in 2025: a molecular era of diagnostic and prognostic classifiers | Mario Cazzola (IT) |
| 14:10 – 14:25 | HCT or not in MDS? How to decide with current prognostic scoring systems | Nico Gagelmann (DE) |
| 14:25 – 14:40 | Are we ready for AI to help in the management of MDS? | Adrian Mosquera (ES) |
| 14:40 – 15:00 | Panel discussion | |
| 15:00 – 15:30 | Coffee break | |
| 15:30 – 16:50 | Session III: MDS treatment | |
| | Chairs: Fernando Barroso Duarte (BR) & Nicolaus Kröger (DE) | |
| 15:30 - 15:45 | Current treatment algorithm in Lower-risk MDS | Maria Teresa Voso (IT) |
| 15:45 - 16:00 | Current treatment algorithm in Higher-risk MDS and the AML/MDS border | Amer Zeidan (US) |
| 16:00 – 16:15 | Therapeutic vulnerability in MDS/AML: looking into the future from the lab standpoint | Jaroslaw Maciaiowski (LLS) |
| 16:15 – 16:30 | Access to genomics and transplant policies in MDS in Latin-America | Jaroslaw Maciejewski (US) Gonzalo Bentolila (AR) |
| 16:30 - 16:40 | Case presentation | Giuliano Filippini Velazquez (DE) |
| 16:40 – 16:50 | Panel discussion | |
| 16:50 – 17:20 | Coffee break | |
| 17:20 – 18:25 | Session IV: Autoinflammation in haematology and beyond | |
| | Chairs: Joanna Drozd-Sokolowska (PL) & Anna Paola Iori (IT) | |
| 17:20 – 17:35 | VEXAS: the lynchpin between inflammation and myeloid neoplasia | Carmelo Gurnari (IT) |
| 17:35 – 17:50 | CMML and autoimmune/inflammatory conditions | Francesco Onida (IT) |
| 17:50 – 18:05 | Incidence and management of HLH in autoimmune diseases | Coralie Bloch (FR) |
| 18:05 – 18:15 | Case presentation | Sarah Leone (US) |
| 18:15 – 18:25 | Case presentation | Syed Ali (AU) |

EBMT

Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy 18-20 September 2025

Friday, 19 September 2025

| 09:00 - 10:10 | Joint Physician-Nurse session HCT in MDS in 2025 |
|---------------|--|
| | Chairs: Maaike de Ruijter (NL) & William Arcese (IT) |
| 09:00 - 09:15 | Which donor to choose in the PtCy era? |
| 09:15 - 09:30 | Bridging or not prior to allo-HCT for MDS? |
| 09:30 - 09:45 | Conditioning regimens in the contemporary era |
| 09:45 - 10:00 | Issues on maintenance and management of relapse |
| 10.00 - 10.12 | Panel discussion |

Kavita Raj (UK) Nicolaus Kröger (DE) Joanna Drozd-Sokolowska (PL) Marie Robin (FR)

Donal McLornan (UK)

Mathieu Puyade (FR)

Nicoletta del Papa (IT)

Gavin Brittain (UK)

Fernando Barroso Duarte (BR)

10:15 – 11:00 Industry Symposium

| 11:00 – 11:30 Coffee break |
|----------------------------|
|----------------------------|

| 11:30 – 12:50 | Session V: HCT in autoinflammation and autoimmunity |
|---------------|---|
| | Chainer Jahr Charvelan (1116) & Andrean Developmentume (1T) |

Chairs: John Snowden (UK) & Andrea Bacigalupo (IT)11:30 – 11:45HCT in VEXAS

- 11:45 12:00 HCT in Behçet's disease
- 12:00 12:15 HCT in systemic sclerosis
- 12:15 12:30 HCT for AID in Brazil: Current Practices
- 12:30 12:40 Case presentation
- 12:40 12:50 Panel discussion
- 12:50 14:00 Lunch break

17:00 - 17:15

| 14:00 – 15:20 | Session VI: Plasma cells as treatment targets in haematology and autoimmune diseases | | |
|---------------|--|--------------------------|--|
| | Chairs: Patrizia Chiusolo (IT) & Paolo Muraro (UK) | | |
| 14:00 – 14:15 | Novel treatment approaches in myeloma | Elisa Roldan Galvan (UK) | |
| 14:15 – 14:30 | Bispecifics in myeloma: bridging to CAR-T? | Patrick Hayden (IE) | |
| 14:30 – 14:45 | Bone marrow plasma cell landscape in health and disease | Farzin Mashreghi (DE) | |
| 14:45 – 15:00 | Plasma cell depletion in autoimmune diseases | Tobias Alexander (DE) | |
| 15:00 – 15:10 | Case presentation | Paulina Piesik (CA) | |
| 15:10 – 15:20 | Case presentation | Jonathan Wickel (DE) | |
| 15:20 – 15:50 | Coffee break | | |
| 15:50 – 17:15 | Session VII: Novel cellular therapies in autoimmune diseases | | |
| | Chairs: Simona Sica (IT) & Dominique Farge (FR) | | |
| 15:50 – 16:05 | Bispecific antibodies in rheumatoid arthritis | Ricardo Grieshaber (DE) | |
| 16:05 – 16:20 | CART in rheumatoid arthritis | Doron Rimar (IS) | |

16:20 - 16:35CAR-T cell therapies in pediatric autoimmune diseases16:35 - 16:50iPS cells for tissue regeneration in autoimmune disease16:50 - 17:00Case presentation

Panel discussion

Ricardo Grieshaber (DE) Doron Rimar (IS) Marco Becilli (IT) Richard Burt (US) Ioanna Minopoulou (DE)

EBMT

Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Preliminary Programme

Rome, Italy 18-20 September 2025

Saturday, 20 September 2025

| 08:45 - 09:45 | Joint Nurse-Physician session HSCT and cellular therapies for autoimmune neurologic diseases Chairs: Claudia Boglione (IT) & Basil Sharrack (UK) | | |
|---------------|---|----------------------------|--|
| 08:45 - 09:00 | Autologous HCT in MS | Alice Mariottini (IT) | |
| 09:00 - 09:15 | CAR T in MS | Lena Kristina Pfeffer (DE) | |
| 09:15 - 09:30 | Cellular therapies in other neurologic indications | Aiden Haghikia (DE) | |
| 09:30 - 09:45 | Panel discussion | | |
| | | | |
| | | | |

10:00 – 10:45 Industry Symposium

10:45 – 11:30 Poster Tour

| | Chairs: Tobias Alexander (DE) & Donal McLornan (UK) | | |
|---------------|---|----------------------|--|
| Poster 1 | What essential information should be included in a patient information leaflet | | |
| | to effectively guide individuals with Multiple Sclerosis (MS) who are considering | 9 | |
| | or undergoing autologous hematopoietic stem cell transplantation (aHSCT)? | Hannah Young (UK) | |
| Poster 2 | Anti-RORI CAR T cells enhanced with safety iCasp9 suicidal gene expression as | | |
| | novel immunotherapy for mantle cell lymphoma | Madalina Nistor (RO) | |
| Poster 3 | er 3 Role of cardiovascular risk stratification in patients undergoing autologous stem | | |
| | cell transplantation for multiple myeloma: a real-life, single-centre evaluation | Ambra Fumagalli (IT) | |
| Poster 4 | To be announced | Giorgia Ranucci (IT) | |
| Poster 5 | To be announced | Lugain Abdalla (UK) | |
| 11:30 – 12:45 | Session VIII: Immune monitoring post CART and late complications for autoimmune disease | | |
| | Chairs: Franco Locatelli (IT) & Raffaella Greco (IT) | | |
| 11:30 – 11:45 | Immune monitoring post-CART | Simona Pagliuca (FR) | |
| 11:45 – 12:00 | Late complications in HCT | Kirill Krigizov (RU) | |
| 12:00 – 12:15 | Late complications in CART | Maeve O'Reilly (UK) | |
| 12:15 – 12:30 | Secondary HLH after CART | Matteo Doglio (IT) | |
| 12:30 – 12:45 | Panel discussion | | |

12:45 – 13:00 Take-home messages from all the organizers